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doi:10.1016/j.jtcvs.2007.11.050500 The Journal of Thoracic and CardObjective: Recent large-scale observational studies have shown better outcomes after
coronary artery bypass grafting than after angioplasty or stenting in patients with mul-
tiple-vessel disease. The time frames of these studies, however, include periods of
varying behavior with respect to patient selection, stent technique and design, and
medical therapy. Our objective was to examine long-term outcomes of coronary stent-
ing and coronary artery bypass grafting, including those performed in the contempo-
rary era of aggressive medical therapy.
Methods: We examined in-hospital and long-term follow-up data from consecutive
patients with multivessel coronary artery disease who underwent isolated initial revas-
cularization by coronary stenting or coronary artery bypass grafting between 1995 and
2003. Cox proportional hazards modeling with propensity scoring and propensity-
based case matching were used to compare long-term survival and correct for baseline
differences between the populations.
Results: A total of 6847 patients were studied (stenting 3917, coronary artery bypass
grafting 2930). Each patient had 1 to 9 years of follow-up (median 3.5 years). Unad-
justed long-termmortalities were similar for coronary artery bypass grafting and stent-
ing (hazard ratio 1.1, 95% confidence interval 0.9–1.2, P5 .21). Matched comparison
of 3488 patients (1856 in each group) with similar likelihoods of undergoing coronary
stenting or coronary artery bypass grafting, however, suggested that coronary artery
bypass grafting provided better long-term survival (hazard ratio 0.7, 95% confidence
interval 0.6–0.9; P 5 .004).
Conclusion: During a 9-year period, in physician-selected patients with favorable
demographic characteristics for both revascularization procedures, coronary artery
bypass grafting was associated with better long-term survival than stent-assisted
angioplasty.
R
ecent large-scale observational studies have reported better outcomes with
coronary artery bypass grafting (CABG) than with coronary stenting in
patients with multivessel coronary artery disease (CAD).1,2 The reported
adjusted hazard ratios [HRs] for the long-term risk of death in these two studies ranged
from 0.43 to 0.76 for patients who underwent CABG relative to patients who under-
went percutaneous coronary intervention (PCI). This divergence in findings from
those of randomized trials calls into question the generalizability of the randomized
trial results to unselected populations and suggests that the selection criteria used in
these trials are an important determinant of PCI performance. The periods encom-
passed by each of these studies, however, predate both thorough understanding of ap-
propriate patient selection and numerous improvements in stent design and in
antithrombotic and antiatherosclerotic medical therapy.
To examine the impact on survival of first-time revascularization with PCI with
coronary stenting instead of elective CABG, we examined long-termmortality amongiovascular Surgery c August 2008
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BARI 5 Bypass Angioplasty Revascularization
Investigation
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
CI 5 confidence interval
HR 5 hazard ratio
MI 5 myocardial infarction
OR 5 odds ratio
PCI 5 percutaneous coronary intervention
THIRDBase 5 Texas Heart Institute Research Database
patients with multivessel CAD enrolled in the Texas Heart
Institute Research Database (THIRDBase). THIRDBase is
a comprehensive, longitudinal clinical registry of outcomes
for more than 150,000 patients treated for cardiovascular dis-
ease at the Texas Heart Institute at St Luke’s Episcopal Hos-
pital. It includes a wide range of data for all patients admitted
to our institution with a diagnosis of cardiovascular disease.
Standard methods of survival comparison (Cox proportional
hazards modeling and propensity-weighted scoring) and
a more stringent statistical method (propensity-based case
matching) were used to make our results comparable with
those of previous studies.
Materials and Methods
Study Population
All patients included in the study were residents of Texas with multi-
vessel CAD who underwent an isolated first revascularization pro-
cedure by either coronary stenting or CABG at the Texas Heart
Institute between January 1995 and December 2003. Patients were
excluded if they had previous CABG, also required a valve opera-
tion, were undergoing primary PCI for an acute myocardial infarc-
tion [MI], had left main CAD, or had a limited life expectancy at
the time of revascularization because of malignancy. Baseline data
on patient characteristics were obtained prospectively for both
groups. Coronary anatomic and procedural characteristics, in-hospi-
tal outcomes, and vital status as of December 31, 2004, were
collected for all patients. Survivorship was determined from the
United States Department of Vital Statistics Database, and follow-
up was complete for 100% of patients. Our long-term survival anal-
yses included both short- and long-term survival data (perioperative
and long-term survivals were not considered separately).
Written, informed consent was obtained at hospital admission
from all patients registered in THIRDBase. All data we analyzed
were stripped of personal identifiers. We obtained approval for
this project from the Committee for the Protection of Human
Subjects, the institutional review board for the University of Texas
Health Science Center at Houston, on November 11, 2004 (HSC-
SHIS-04-009).
Patient histories were obtained by interview at hospital or
clinic presentation and were entered prospectively into the data-
base. Variables defined were the number of diseased vessels,
left ventricular ejection fraction, urgency of the procedure, hyper-The Journal of Thtension (defined as blood .130/90 mm Hg or current use of anti-
hypertensive medications), angina severity (defined according to
the Canadian Cardiovascular Society classification system), con-
gestive heart failure severity (classified according to New York
Heart Association criteria), family history of CAD, previous MI,
renal insufficiency (defined as a serum creatinine level $2 mg/
dL), diabetes mellitus (defined as a fasting blood sugar level
.125 mg/dL or the use of antidiabetic agents), peripheral vascular
disease, transient ischemic attack, cerebrovascular disease,
abdominal aortic aneurysm, and chronic obstructive pulmonary
disease.
Statistical Analysis
The Pearson c2 test was used to analyze discrete variables, and the
Student t test was used to analyze continuous variables. Logistic re-
gression and Cox proportional hazard models that used a forward
stepwise variable selection process were developed to determine
which clinical and angiographic variables were associated with
late mortality. This HR (or odds ratio [OR]) is the ratio of the mor-
tality in the stenting group to that in the CABG group at any given
point in time, controlling for differences in patient demographic
characteristics or risk factors.
To express survival differences in percentages, long-term mor-
tality was evaluated with Cox proportional hazards modeling,
with propensity scoring to adjust for differences in baseline charac-
teristics influencing each patient’s likelihood of being treated with
stenting versus CABG, and with an analysis that involved stringent
case matching according to propensity scores. Propensity scores
were computed from as many patient characteristics and early out-
come variables as possible. For the case-matched study population,
pairs of patients with similar propensity scores were selected from
the two treatment groups. This method yielded very similar stenting
(n5 1856) and CABG (n5 1856) groups, which were compared in
subsequent late-outcome analyses. Analyses were performed with
SAS 6.09 software (SAS Institute, Inc, Cary, NC) for the VAX/
VMS operating system.
Results
Patient Characteristics
Between 1995 and 2004, a total of 6847 patients with multi-
vessel CAD (CABG n 5 3917, stenting n 5 2930) who un-
derwent an isolated first revascularization procedure and who
were enrolled in the THIRDBase were included in this study.
Follow-up extended up to 9 years, with median durations of
3.0 years (25th–75th interquartile range 2.0–7.4 years) for the
stenting group and 3.9 years (25th–75th interquartile range
1.1–5.0 years) for the CABG group.
The prevalences of diabetes (33%) and reduced left ven-
tricular systolic function (ejection fraction ,50%, 32%)
were high in this study population, particularly in the
CABG group (Table 1). The CABG group also had higher
prevalences of advanced age, male sex, smoking, previous
MI, unstable angina, congestive heart failure, peripheral vas-
cular disease, cerebrovascular accident, and chronic obstruc-
tive pulmonary disease. Of the listed variables, only
hypercholesterolemia, obesity, and female sex were moreoracic and Cardiovascular Surgery c Volume 136, Number 2 501
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CDTABLE 1. Patient data according to revascularization method
CABG (n 5 2634) Stenting (n 5 3845) P value
Demographic data
Mean age (y) 62.5% 61.7% .015
Age .65 y 45.1% 43.7% .23
Female 26.0% 27.1% .29
Risk factors
Diabetes mellitus 37.6% 29.4% ,.001
Insulin requirement 12.0% 7.4% .001
Hypertension 74.8% 75.5% .59
Hypercholesterolemia 58.4% 66.2% ,.001
Smoking 49.8% 47.8% .11
Obesity (body mass index .26 kg/m2) 19.6% 21.2% .11
Other medical history data
Family history of coronary artery disease 36.2% 38.3% .075
History of myocardial infarction 34.1% 29.5% ,.001
History of unstable angina 54.2% 52.1% .079
History of congestive heart failure 13.9% 11.7% .009
New York Heart Association functional class IV 11.1% 10.4% .38
History of nonsurgical valve disease 4.8% 5.5% .16
History of peripheral vascular disease 17.8% 15.8% .025
History of chronic renal insufficiency 12.2% 12.2% .99
Previous cerebrovascular accident 5.9% 5.0% .097
History of chronic obstructive pulmonary disease 22.9% 19.6% .001
Angiographic data
Disease type and extent ,.001
Two-vessel disease 23.1% 72.8%
Three-vessel disease 73.5% 27.2%
Left ventricular function ,.001
Ejection fraction $50% 64.0% 71.1%
Ejection fraction 35%–49% 24.6% 20.8%
Ejection fraction #34% 11.3% 8.1%
Urgent procedure 5.7% 4.9% .16
CABG, Coronary artery bypass grafting.common in the stenting group. Most patients in the CABG
group (76%) had three-vessel CAD, whereas those in the
stenting group had a more variable degree of CAD: 72%
had two-vessel CAD, and 27% had three-vessel CAD. Ur-
gent procedures accounted for 5.3% of all cases (5.7% for
CABG, 4.9% for stenting, P 5 .1571).
Patients in the CABG group each had an average of 3.4
distal anastomoses performed. A left internal thoracic graft
to the left anterior descending coronary artery was used in
93% of patients. In the stenting group, glycoprotein IIb and
IIIa inhibitors were used in 18% of stenting procedures.
Predictors
Several significant predictors of mortality were identified
(Table 2). The multivariable logistic regression model
showed that the strongest predictors of mortality in the
CABG group were age older than 65 years (OR 2.2, 95%
confidence interval [CI] 1.8–2.7) and history of chronic renal
insufficiency (OR 1.9, 95% CI 1.5–2.3). The significant pre-
dictors of mortality in the stenting group included age older502 The Journal of Thoracic and Cardiovascular Surgery c Athan 65 years (OR 2.8, 95% CI 2.1–3.8) and history of
chronic renal insufficiency (OR 2.2, 95% CI 1.6–3.1).
Short-term Survival Analysis
Adjusted in-hospital mortality was higher in the CABG
group than in the stenting group (2.0% vs 0.3%, P ,
.0001). Risk of in-hospital death was also higher in the
CABG group (HR 2.9, 95% CI 1.7–4.7). Additionally,
CABG was associated with greater risks of Q-wave MI
(3.6% vs 1.0%, P , .0001) and periprocedural major stroke
(2.5% vs 0.2%; P , .0001) than was stenting. A higher rate
of repeat revascularization during initial hospitalization was
noted in the stenting group (0.1% vs 2.5%, P , .0001).
The rates of the composite in-hospital end point of death,
MI, stroke, and repeat revascularization were 7.3% in the
CABG group and 4.0% in the stenting group (P , .0001).
Long-term Mortality
Unadjusted long-term mortality was similar between the
CABG group and the stenting group (OR 1.1, 95% CIugust 2008
Kohsaka et al Surgery for Acquired Cardiovascular DiseaseTABLE 2. Variables associated with long-term mortality in Cox regression analysis
CABG Stenting
Odds ratio 95% Confidence interval Odds ratio 95% Confidence interval
Age .65 y 2.2 1.8–2.7 2.8 2.1–3.8
New York Heart Association functional class IV 1.5 1.1–2.0 NS
History of valve disease not treated surgically 1.6 1.1–2.0 NS
History of chronic obstructive pulmonary disease 1.5 1.2–1.8 NS
Previous cerebrovascular accident 1.6 1.2–2.2 NS
History of peripheral vascular disease 1.7 1.4–2.1 NS
History of chronic renal insufficiency 1.9 1.5–2.3 2.2 1.6–3.1
History of congestive heart failure 1.8 1.4–2.3 2.1 1.3–3.4
Diabetes mellitus 1.6 1.3–2.1 1.7 1.1–2.6
CABG, Coronary artery bypass grafting; NS, not significant.1.0–1.2, log-rank test P5 .27). After adjustment with a mul-
tivariate model, no difference in mortality was observed be-
tween the CABG and stenting groups (OR 0.9, 95% CI
0.7–1.1). Propensity adjustment, however, revealed a rather
strongly favorable result for surgically treated patients (HR
0.8, 95% CI 0.7–0.9, P 5 .0005).
Matched Groups
We matched 3712 patients (1856 from each group) with re-
spect to their likelihood of being assigned to undergo
CABG or stenting according to their clinical, angiographic,
and demographic characteristics (Table 3). Between theseThe Journal of Thortwo groups, there were no significant differences in age,
sex distribution, or the prevalences of current smoking, dia-
betes, hypercholesterolemia, presentation with unstable an-
gina, or history of MI. The angiographic characteristics of
both groups of patients were also similar; both groups had
large proportions of patients with two-vessel CAD. The aver-
age number of totally occlusive lesions was 1.2 in the CABG
group and 1.4 in the stenting group (P5 .049). Similar to the
outcome of adjusting observed values, the matched popula-
tion without adjustment in observed values revealed a signif-
icant difference in favor of surgery at 9 years (HR 0.7, 95%
CI 0.6–0.9, P 5 .004).A
CDTABLE 3. Patient data by revascularization procedure in case-matched patients
CABG (n 5 1856) Stenting (n 5 1856) P value
Demographic data
Age .65 y 41.0% 42.0% .54
Female 28.9% 27.7% .41
Risk factors
Any diabetes mellitus 28.9% 28.8% .94
Hypertension 72.1% 71.7% .78
Hypercholesterolemia 65.0% 62.8% .17
Smoking 50.3% 49.5% .62
Obesity (body mass index .26 kg/m2) 19.5% 19.3% .86
Other medical history data
Family history of coronary artery disease 38.3% 40.0% .30
History of myocardial infarction 10.3% 11.3% .33
History of unstable angina 58.4% 55.9% .12
History of congestive heart failure 12.1% 11.7% .75
New York Heart Association functional class III or IV 68.6% 68.8% .91
History of valve disease 4.6% 3.9% .31
History of peripheral vascular disease 15.3% 14.3% .42
History of chronic renal insufficiency 12.1% 10.1% .06
Previous cerebrovascular accident 4.2% 4% .67
History of chronic obstructive pulmonary disease 20.2% 19.4% .58
Urgent procedure 5.7% 4.7% .22
Totally occlusive lesions per patient (mean no.) 1.2 1.4 .049
CABG, Coronary artery bypass grafting.acic and Cardiovascular Surgery c Volume 136, Number 2 503
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CDTABLE 4. Large-scale observational studies of percutaneous coronary intervention versus coronary artery bypass grafting
with long-term follow-up
Thoraxcenter,7
1995–1999
Cleveland
Clinic,1 1995–1999
New York
State,2 1997–2000
Northern New
England,6 1994–2001
Current study,
1995–2004
CABG PCI CABG PCI CABG PCI CABG PCI CABG PCI
Mean follow-up (y) 7 5.2 1.9 1.6 3.6 3.5
No. of patients 409 1640 5161 872 22,102 37,212 4295 10,198 2930 3917
Received stents NA 100% NA 70% NA 100% NA 64% NA 100%
Mean age (y) 63 61 64 65 67 65 64 62 63 62
Diabetes mellitus 15% 23% 40% 30% 33% 25% 34% 26% 37% 30%
History of chronic
renal insufficiency
—* —* 3% 6% 3% 6% 3% 2% 12% 12%
Three-vessel disease 80% 23% 74% 33% 69% 19% 50% 13% 73% 27%
Depressed (,50%) left
ventricular EF
23% 13% Mean EF 54% NR 19% 14% 6% 36% 29%
Mortality
30-d 0.2% 1.0% 1.3% 1.1% 1.8% 0.7% 1.7%y 0.5%y 1.4%y 0.3%y
Long-termz 0.59 (0.38–0.9) 0.43 (0.35–0.54) 0.64–0.75 0.86 (0.77–0.97) 0.8 (0.7–0. 9)
CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention; NA, not applicable; EF, ejection fraction; NR, not reported. *Excluded by
design. yRisk-adjusted 30-day mortality. zLong-term mortality data are reported as hazard ratios.Discussion
The patients included in this study represent a broad popula-
tion of patients with CAD of varied clinical presentation who
would be candidates for either CABG or stenting in the cur-
rent era. Reflecting current clinical practice, CABG was gen-
erally reserved for patients with higher-risk profiles, more
lesions, and worse left ventricular systolic function. The re-
sults of our survival analysis, stringently adjusted for these
confounding factors—including number of diseased ves-
sels—suggest that, for primary revascularization at least, per-
forming CABG rather than PCI with stenting carries a greater
short-term cost in terms of complications and mortality but
provides more effective protection and improved survival
in the long term.
Our findings have variable companionship in the litera-
ture. The Bypass Angioplasty Revascularization Investiga-
tion (BARI) found poorer 7-year survival after angioplasty
(65%) than after CABG (80%) in patients being treated for
diabetes.3 A separate analysis of BARI registry data4 dis-
agreed with those of randomized trial data with respect to
the outcomes of patients with diabetes: patients with diabetes
treated percutaneously and those treated surgically had iden-
tical survival rates (84%) during 7 years. A review of the
characteristics of the percutaneously treated patients in the
BARI trial and registry5 found that registry patients treated
percutaneously had fewer lesions at baseline and that their
lesion characteristics were more favorable for PCI. These ob-
servations highlight the impact of patient selection on long-
term outcome after a PCI procedure.
During the performance and follow-up of several random-
ized trials comparing angioplasty with CABG, the coronary504 The Journal of Thoracic and Cardiovascular Surgery c Augstent was introduced and rapidly became a standard of care.
Many clinicians assume that stenting is more beneficial for
long-term survival than is angioplasty alone, but this assump-
tion has not been tested in a randomized trial. Our data sug-
gest that in an unselected population of patients with
multivessel CAD first revascularization with CABG is asso-
ciated with better survival rates than those associated with
coronary stenting. These results are in agreement with those
of similarly designed large-scale retrospective studies, de-
spite differences in study design and population (Table 4).
In the Cleveland Clinic,1 New York State Registries,2 North-
ern New England,6 and Thoraxcenter7 database analyses,
CABG was associated with lower long-term mortality than
was stenting.
On the other hand, our findings contradict those of the
Stent or Surgery trial (SoS),8 ERACI II,9, and Randomized
Intervention Treatment of Angina (RITA)10 randomized tri-
als. Like BARI and the trials of balloon angioplasty without
stenting, these three studies found no difference in 5-year sur-
vival between patients treated with stenting or CABG. Also
like BARI, these studies found that patients with diabetes
may fare slightly less well when treated percutaneously. In
our study, the improved survivals in the CABG group in
both the risk-adjusted analyses and the case-matched com-
parison suggests that our findings were not merely the result
of an unequal distribution of risk factors. An intriguing po-
tential explanation for the difference between our results
and those of other randomized trials is the inclusion in our
study of patients with treatment similar to current practice
patterns. After the publication of the BARI data and the accu-
mulation of experience with long-term stent failure byust 2008
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heterogeneous. Our institution’s increasing tendency during
recent years to use PCI (rather than surgical) therapy in pa-
tients with complex or bifurcation lesions and in patients
with diabetes and severe CADmay be responsible for the dif-
ferences between our results and those of randomized con-
trolled trials in terms of the outcomes of the two treatment
strategies.
Moreover, CAD progression during follow-up is a poten-
tial adverse outcome of both techniques.11). Medical therapy,
including the routine use of angiotensin-converting enzyme
inhibitors, long-term dual antiplatelet therapy, and far more
aggressive lipid-lowering therapy, has evolved significantly
since the previous registry studies were published. Both sa-
phenous vein grafts and native vessels receive the protection
of more aggressive medical therapy. Still, CAD progression
does occur. Failure of a percutaneously treated vessel be-
cause of lesion progression at an untreated site may have
greater impact on the subtended tissue than does lesion pro-
gression after CABG, in which two or more vessels may
share the responsibility (albeit unevenly). As a result, patients
who undergo CABG may receive greater relative benefit
from these medical innovations while being less susceptible
to catastrophe in the case of CAD progression than those
who undergo PCI. Attempts to treat percutaneously patients
or vessels in which eventual treatment failure is probable
(eg, patients with diabetes mellitus, extensive atherosclerotic
burden, small vessels with long lesions, or bifurcations) may
highlight this contrast between the two revascularization
methods.
Hannan and colleagues2 used the powerful New York
State revascularization reporting system to examine out-
comes in more than 59,000 patients treated between 1997
and 2000. Patients with previous revascularization proce-
dures and left main coronary artery stenosis were excluded.
Survival after 3 years was better in the stenting group than
in the CABG group. After adjustment for baseline risk fac-
tors, however, CABG was associated with superior survival
not only in the population as a whole but, surprisingly, in al-
most every subgroup examined, including patients with two-
vessel CAD without left anterior descending coronary artery
involvement.
Brener and associates1 examined the survivals of patients
treated surgically or percutaneously at the Cleveland Clinic
from 1995 to 1999, excluding patients who had been refused
treatment by a cardiac surgeon because of ‘‘comorbidity or
a lack of appropriate target vessels’’ and patients who were
undergoing primary treatment for acute MI, who died during
the procedure, or who had no social security number. Only
70% of the percutaneously treated patients underwent stent
implantation. After 5 years, survivals were similar in patients
who underwent PCI (16%) and those who underwent CABG
(14%), despite the fact that the CABG group had more risk
factors at baseline. After propensity matching was used toThe Journal of Thcorrect for this difference in baseline risk, the CABG group
appeared to have superior survival (OR 2.3, 95% CI 1.9–
2.9). We also excluded patients with acute MI in this study,
but we included patients with any other high-risk surgical
profile, and our PCI population was restricted to those who
received stents.
The Thoraxcenter study7 examined a population similar in
size and characteristics to that of the Cleveland Clinic study,
save that only patients who received a stent in two or more
vessels were included. The finding that 8-year survival was
marginally better in the CABG group (87.5%) than in the
stenting group (82%) (P 5 .06) was driven almost solely
by the inclusion of patients with left main CAD.
Additionally, the Cleveland Clinic1 and Northern New
England6 studies included patients treated with balloon an-
gioplasty only (without stenting). In contrast, the New
York State Registries2 and Thoraxcenter7 trials restricted
their PCI populations to stent recipients; however, these
two studies differed substantially in the demographic charac-
teristics of their populations.
Limitations
Even large observational studies such as this one can be bi-
ased by baseline differences between treatment groups. The
main limitation of this study is that although the observations
that prompted physicians to refer patients for coronary revas-
cularization may be important markers of outcome, we could
not obtain these data. We have attempted to nullify the effects
of these data and other potential confounding variables by
using Cox and propensity analysis. The differences in the
results of the Cox and propensity analyses are a source of
interest. Although it is possible that propensity adjustment
overcorrects for differences in baseline variables, this seems
unlikely given the results seen in the matched populations. A
more probable explanation is that the ability of the propor-
tional hazards model to separate the effects of individual
variables may exclude the effect of physician judgment. Pro-
pensity adjustment or matching by examining the confluence
of variables affecting referral for a given procedure may be
a more powerful means of statistical adjustment for a study
such as this.
Long-term follow-up data on the need for repeat proce-
dures or control of angina were not available. It is well estab-
lished, however, that CABG is more reliable than bare-metal
stenting in preventing symptom recurrence and the need for
repeat procedures. Our goal was to examine the effect of
that difference on long-term survival in a nonrandomized
population.
A limitation of both our study and all other comparative
studies of CABG and PCI is that their findings may quickly
be outdated by technologic advances. One such advance is
the advent of drug-eluting stents, which dramatically reduce
the need for repeat revascularization after stent placement.
There is not yet clear-cut evidence, however, that these stentsoracic and Cardiovascular Surgery c Volume 136, Number 2 505
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about comparative survival from populations with bare-metal
stents. Additionally, uses of adjunct devices, such as cutting
balloon, laser, and rotational atherectomy, although rare in
our population, were not recorded, so the influences of such
devices on outcome are not known. Further, advances in pre-
operative evaluation, including more precise coronary artery
and myocardial imaging and diagnostic techniques, have al-
lowed more appropriate patient selection and surgical plan-
ning. Improvements in cardiopulmonary perfusion and
careful myocardial protection, as well as the use of off-pump
and on-pump beating-heart techniques in selected cases,
have also decreased perioperative morbidity and mortality.
Implications
In this large, longitudinal database study performed during
the modern era of percutaneous coronary stenting, physi-
cian-selected strategies for first-time revascularization with
CABG were associated with better long-term survival than
was stent-assisted angioplasty.
We thank Stephen N. Palmer, PhD, ELS, who provided editorial
support.
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